Gibson Dunn Advises 89bio on $287.5 Million Offering of Common Stock and Pre-Funded Warrants
Firm News | February 3, 2025
Gibson Dunn represented 89bio, Inc. in a public offering of common stock and pre-funded warrants that generated aggregate gross proceeds of approximately $287.5 million to 89bio. Goldman Sachs & Co. LLC, Leerink Partners, and BofA Securities acted as lead book-running managers, and Cantor acted as book-running manager for the offering.
89bio is a clinical-stage biopharmaceutical company dedicated to the development of therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is headquartered in San Francisco.
Gibson Dunn regularly advises life sciences companies and investors on complex capital markets transactions in the biopharmaceutical sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Lauren Navarro, and Jasmine Vitug.